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ABSTRACT: The aqueous properties of the drugs Sorafenib, Lapatinib, Geﬁtinib,
Fulvestrant, and Clofazimine were explored to monitor their tendency to self-associate. A
combination of nuclear magnetic resonance, dynamics light scattering, and electron and
confocal microscopies found that they tended to form large nano-entities having distinct types
and sizes and were capable of entering cells. The combination of strategies employed serves to
detect and reveal nano-entities along with their three-state equilibria and behaviors in buﬀers,
media, and cells.
■ INTRODUCTION
The drug discovery community has recognized that the
physicochemical attributes of compounds can somehow
predispose them to many properties,1−9 so pharma workﬂows
focus on prioritizing compound candidates that exhibit
favorable properties and deprioritizing those that have
undesirable properties. For this, extensive characterization
eﬀorts are undertaken.
For many reasons, these characterization eﬀorts are executed
and interpreted within the context that compounds in aqueous
solvent behave predominantly as either single-molecules in
solution or as a solid form such as precipitates. However, it is
becoming more apparent that each compound exists in a
unique three-phase equilibrium in solution between single
lone-tumbling molecules, self-associated aggregates (nano-
entities), and solid forms. Although this revised view
recognizes the existence of this intermediate aggregate phase,
it is becoming clear that drugs can form a wider range of self-
assembled nano-entities than previously expected.10,12
To date, little is known about the full range of types and
sizes of self-assemblies that drugs can adopt. There have been
reports that some can form colloidal aggregates, whereas others
can form much smaller multimers.10 One of the main issues for
properly characterizing these nano-entities is insuﬃcient
detection strategies, which explains our poor knowledge of
this phenomenon and the resultant properties.11−14 No single
technology can detect the full range of nano-entities that can
exist, but each technology has its advantages and limitations.
For example, dynamics light scattering (DLS) and transmission
electron microscopy (TEM) are sensitive to large colloidal
assemblies (e.g., nanometer size) but are less optimal for small
entities and mixtures. nuclear magnetic resonance (NMR)
spectroscopy, on the other hand, is highly sensitive to small- to
medium-sized aggregates (Ångstrom to subnanometer sizes).
This technology can also be used to monitor large aggregates
although it requires breaking the aggregates into smaller
entities using detergents for detection purposes. Also, confocal
laser scanning microscopy (CLSM) can be employed to
monitor drugs in cells, but the compounds must be ﬂuorescent
and form suﬃciently large assemblies. Other potential
detection methods can also be used such as nephelometry,
SPR, MST, DOSY NMR, and CPMG NMR.
Establishing appropriate detection strategies will be central
for thoroughly correlating nano-entities with their respective
properties. Impressive examples have already begun to emerge
that demonstrate serious impact on drug discovery eﬀorts.
Compound and drug aggregates have been attributed to the
observation of promiscuity and high incidences of false-
positives in high-throughput screens for lead discovery.13,14
They have also been implicated in aﬀecting the eﬃcacy of
drugs in cell culture assays because of lack of cell membrane
permeability.15 This has helped to explain the “bell-shaped”
concentration response curves for formulated drugs.16
Furthermore, they have been responsible for giving rise to
promiscuity in vitro, oﬀ-target pharmacology assays and
toxicity alerts.10 Interestingly, aggregates have also been
associated with beneﬁcial attributes such as enhancing
exceptional drug oral bioavailability.17 One can also envisage
drug nano-entities as potential drug carriers or even delivery
systems.
Here, we use several anticancer drugs (Sorafenib, Lapatinib,
Geﬁtinib, and Fulvestrant) and an anti-leprosy drug
(Clofazimine) as model systems to explore various techniques
for monitoring their physicochemical solution behavior. We
evaluate data from NMR, DLS, TEM, and CLSM to
characterize the nano-entities formed and to probe the
strengths and limitations of the methods. It should be kept
in mind that the present study focuses on compounds that
form the large colloidal aggregates. Studies involving the
smaller nano-forms are referred to an early report and to
forthcoming disclosures.10,12
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■ RESULT AND DISCUSSION
A typical workﬂow practiced in the pharmaceutical industry is
one where medicinal chemists synthesize new compounds
based on design concepts intended to capture a range of
intended favorable properties, for example, binding and
speciﬁcity for a target protein, bioavailability, stability, and
safety.
Medicinal chemists almost exclusively characterize their
candidate drugs in organic solvents, then lyophilize, and
expedite the powders or stock solutions to multiple other
laboratories for a broad range of pharmaceutical tests where
the compounds are dissolved in or diluted with aqueous media.
However, drugs behave much diﬀerently in organic solvents as
compared to aqueous media, and thus the above workﬂow
introduces an important and uncharacterized disconnect. That
is, no one along the workﬂow is responsible for monitoring a
compound’s aqueous behavior in solution for the aggregate
phasethus, the three-phase equilibrium systematically goes
largely unexplored.
This is unfortunate because a simple and quick perusal of the
1H NMR spectrum of a compound in buﬀer can easily begin to
expose features of its three-state equilibrium.12 This is
illustrated in (Figure 1) for the four compounds (Sorafenib,
Lapatinib, Clofazimine, and Geﬁtinib). From 20 mM stock
solutions in DMSO-d6, compounds were diluted in DMSO-d6
solvent to 200 μM concentration where it was noted that they
dissolved wellclear solutions were observed with no
precipitate. 1H NMR spectra of the later samples (200 μM)
were then acquired, respectively, and shown in Figure 1a. This
atomic view of hydrogen nuclei shows that all resonances are
observable and sharp, as expected for compounds that behave
as single lone-tumbling molecules in solution.
Samples of these compounds at 200 μM in aqueous buﬀer
were then prepared by placing aliquots of DMSO-d6 stock
solutions into aqueous buﬀer followed by gentle agitation.
Some cloudiness or solid precipitate was noted, and so the
samples were subjected to light centrifugation. The super-
natant was then placed in NMR tubes and 1H NMR spectra
acquired. Figure 1b shows that no NMR resonances were
observed. It is possible that the compounds totally existed as a
solid-state form and were removed by this latter manipulation.
Even if some solid remained as a cloudiness, the resonances of
solids are too broad to be observed by solution NMR. Another
possible explanation would be that the compounds partitioned
between precipitates and very large self-associated and soluble
aggregates. The latter would have to tumble too slowly in
solution which would also result in resonances that are too
broad to be observed by solution NMR. Interestingly, we
showed in a previous report that a simple trick of adding a
detergent such as Triton or Tween to the samples induced the
breakup of the large aggregates, resulting in faster tumbling
lone molecules, which then gave rise to observable NMR
resonances. To our surprise, the addition of detergent to the
Figure 1. NMR spectra of four compounds. (a) Compounds in DMSO-d6 at 200 μM, (b) compounds in buﬀer at 200 μM, (c) compounds in the
presence of Tween 80, (d) DLS data for the four compounds. Both techniques involving buﬀer contained 50 mM sodium phosphate, 100 mM
NaCl, 10% D2O, pH 7.4 in the absence and presence of 0.025% (v/v) Tween 80 for 24 h.
Figure 2. TEM images of four anticancer drugs (Fulvestrant, Sorafenib, Lapatinib, and Geﬁtinib), and an antileprosy drug (Clofazimine), (a) 50
μM of compounds incubated for 24 h in DMEM 5% FBS, or (b) in DMEM with no FBS, or (c) in phosphate buﬀer pH 7.4. Bars represent 100 nm.
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Sorafenib sample did not give rise to sharp resonances (see
Figure 1c), whereas sharp resonances did arise for Lapatinib,
Clofazimine, and Geﬁtinib (see Figure 1c). The latter
observations unequivocally report the existence of the large
aggregates. However, the lack of resonances for Sorafenib
demonstrates our assumptions and limited knowledge of
aggregate types and how to manipulate and observe them by
NMR.
Interestingly, DLS data acquired on the aqueous samples,
after light centrifugation, clearly showed existence of the
nanometer-sized aggregates (see Figure 1d). The DLS data of
these samples after the subsequent addition of detergent report
diﬀerential changes in aggregate sizes, which demonstrated the
potential complementarity of NMR and DLS techniques. TEM
also convincingly revealed the presence of very large aggregates
in various media such as Dulbecco’s modiﬁed Eagle’s medium
(DMEM) with 5% fetal bovine serum (FBS) (see Figure 2a),
cell culture media (DMEM) without (FBS) (see Figure 2b),
and aqueous phosphate buﬀer (see Figure 2c). Similar
experiments and conditions were also reported by others in
which they found that the behaviors of the three anticancer
drugs Lapatinib, Fulvestrant, and Sorafenib are consistent with
the formation of colloidal aggregates in phosphate buﬀer and
in cell culture media 10% FBS for 24 h at 37 °C.15
First, it must be kept in mind that our samples were
prepared by soaking the compound solutions with a carbon-
coated copper grid which is required for TEM observation
purposes. Also, it is expected that lone-tumbling single
molecules (tumbling radius on the single digit Ångstrom
scale) would be invisible by TEM which is sensitive to species
that have radii on the double-digit nanometer scale. Keeping
these considerations in mind, a number of observations can
nonetheless be made for characterizing these intriguing and
large nano-entities observed (see Figure 2).
Interestingly, a comparison of the horizontal images along
(Figure 2c) shows a variety of large aggregates for the drugs in
buﬀer. Some are smaller such as that found for Clofazimine,
whereas very large globs are noted for Fulvestrant, Sorafenib,
and Lapatinib. A range of sizes are also noted. Geﬁtinib
appears as a solid-like form. Changes in the aggregates are
notable when the compounds are soaked in DMEM media
compare Figure 2a with 2b. Likewise, dramatic changes are
observed when comparing all three media conditions (see
Figure 2a−c). We then studied the eﬀect of adding detergent
to large nano-entities. The addition of detergents to samples
suspected of forming large aggregates is a widely used strategy
in many biochemical assays to reveal false-positive hits in
screening campaigns.
One typically runs screening campaigns to identify lone-
tumbling compounds that inhibit a protein, but these assays
are frequently contaminated with false-positive hits from
compounds which form large aggregates and inhibit via
nonstoichiometry and nonspeciﬁc means. Running follow-up
validation screens typically involves the addition of a detergent,
which presumably breaks up drug aggregates, and results in the
loss of false-positive inhibition.
We thus explored the eﬀect of the addition of detergents on
the aggregates of the drugs studied here (see Figure 3a). The
TEM images shown in Figure 3a for Sorafenib, Lapatinib, and
Clofazimine (in the absence of detergent) clearly display large
aggregates. Upon addition of 0.025% Tween 80 detergent, the
TEM images in Figure 3b show that these large aggregates
have been seriously altered and disrupted. Taking the 1H NMR
experiments in Figure 1 into account, it is clear that addition of
detergent breaks the aggregates into very small tumbling
entities for Lapatinib and Clofazimine, which is consistent with
the TEM changes in Figure 3b. However, small entities were
not observed for Sorafenib upon addition of detergent, whereas
the TEM data clearly shows disruption of the large aggregates.
Therefore, the example of Sorafenib demonstrates that
solubility is limited, or more likely here, there might be
aggregate types that NMR and TEM simply cannot detect.
This suggests that each compound can assume its unique
ﬁngerprint of self-assemblies, thus one must remain vigilant
regarding assumptions and dogma in this ﬁeld of study.
Two notable and contentious assumptions are that
compound aggregates cannot exist in plasma nor be able to
cross membranes to enter cells.18 The former assumption has
often been rationalized, given that many drugs have been
found to be highly serum-bound in vivo.19 Given this, the
majority of a compound would be expected to be bound to
serum proteins such as albumin, leaving compounds mostly
unavailable to self-associate. This assumption is unfounded. In
a previous study, involving an NMR aggregation test, it was
Figure 3. (a) TEM images of 50 μM Sorafenib, Lapatinib, and Clofazimine incubated for 24 h at 37 °C in DMEM 5% FBS in the absence of
0.025% (v/v) Tween 80, (b) in the presence of 0.025% (v/v) Tween 80. Bar represent 100 nm.
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clearly shown that aggregating compounds remained self-
associated in a range of pharmacology buﬀers, plasma, and
blood. This would suggest that there is a signiﬁcant aﬃnity for
self-association for some compounds.10 It has also recently
been reported that Evans Blue forms colloids that adsorb
albumin.15
Regarding these assumptions, we set out here to identify
tools that can help determine if aggregating compounds can
cross membranes and enter cells. Others assumed that
aggregates are too large and cannot diﬀuse through cell
membrane of live cells.16 For our study, we explored the use of
CLSM. First, one must realize and consider that all the
methods used here make observations at very distinct
resolutions. NMR makes measurements at the atomic level
or Ångstroms, whereas TEM and DLS resolve particles at the
nanometer scale, and CLSM at the micrometer level. Thus,
CLSM is the most appropriate method for observations at the
cellular level. However, to render a compound observable by
CLSM, it must have inherent ﬂuorescence, so we were limited
in the compounds that could be studiedthus, potential
compounds were prescreened by a standard ﬂuorescent
microscope.
We began this study by the incubation of HeLa cells in the
presence of Lapatinib at 50 μM for 24 h and acquired CLSM
views (see Figure 4a). Data from a range of other
concentrations, conditions, and compounds are provided in
the Supporting Information, along with a description of the
procedures employed and experimental information. Figure 4a
shows that the green ﬂuorescent of Lapatinib indeed had
entered the cell and appears mostly localized to the cytoplasm.
Note that the cell membrane and nuclei can be visualized (see
Figure 4a) based on the red and blue dyes Alexa Fluor 555
conjugate of WGA and DRAQ5, respectively, which are well-
known markers. Interestingly, Lapatinib appears to be well-
distributed within the cytoplasm given that green ﬂuorescence
is observed for all the cytoplasm.
We also measured the antiproliferative activities of aggregate
form (no Tween) and monomer forms (+Tween) of Lapatinib
on HeLa cells. Our study found that both forms exhibit similar
antiproliferative activities suggesting that both forms are
capable of entering HeLa cells (see Supporting Information,
Figure S6). Note that we and others conﬁrmed that 0.025% of
Tween 80 was nontoxic (Supporting Information).15 In
contrast, others found that the monomer form had signiﬁcantly
improved activity versus the aggregate form using MDA-MB-
231 cells, suggesting that the monomer form has better
capability of entering cells as compared to the aggregate from.
Thus, aggregate penetration is likely cell type-dependent.
Further CLSM studies were then focused on another
compound Clofazimine, and distinct ﬁndings were observed.
Clofazimine was incubated with Huh-7 cells for 1 hour (see
Figure 4b). Although Figure 4b shows a well-distributed green
ﬂuorescence within the cytoplasm, there are stronger
compound signals arising from the nucleus. Note that the
nuclei can be visualized (see Figure 4b) based on the blue dye
DAPI, but the cell membrane cannot be easily distinguishable
given that no Alexa Fluor 555 conjugate of WGA dye was
added in this experiment because of signal interferences. In
order to verify that the compound aggregates were occurring
intra- and not extra-cellularly, care was taken to wash the cells
after the incubation step. They were washed twice in
phosphate-buﬀered saline (PBS) to remove any existing
extracellular aggregates, and fresh DMEM 5% FBS were
added to the cells.20
It is also interesting that Clofazimine is considered as a
lipophilic antibiotic which has very long pharmacokinetic half-
life of up to 70 days.20 It was noted that Clofazimine
aggregates/accumulates in cells (in vitro) over several days,
where it formed intracellular inclusions in the cytoplasm.
Perhaps the long half-life is related to sequestering via
aggregation. It was also reported that Clofazimine can be
toxic as it induces changes to the mitochondria structure and
function. Also, Clofazimine has reported to form stable
complexes with DNA and transfer RNA, which resulted in
spectral red shifts.21 In our study, no red shifts were observed
Figure 4. (a) Confocal images of HeLa cells incubated in the
presence of 50 μM Lapatinib for 24 h. Alexa ﬂuor WGA 555 was used
to stain cell membranes and DRAQ5 to stain the nucleus. (b) Huh-7
cells incubated in the presence of 50 μM Clofazimine for 24 h. DAPI
was used to stain the nucleus. Bar represents 20 and 10 μm.
Figure 5. USEM images of HeLa cells incubated for 24 h in the presence of (a) 50 μM Lapatinib, (b) 50 μM Clofazimine, and (c) 50 μM Light
green SF yellowish, (d) represents control cells in the absence of drugs. Bar represent 500 nm.
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and detections were made using the same green emission
wavelengths in the nucleus and cytoplasm.
Our study also employed ultrathin section electron
microscopy (USEM) to observe aggregates within cells but
as a complementary technique with higher resolution at the
nanometer scale. Figure 5 shows USEM images involving
Clofazimine, Lapatinib, and Light green SF yellowish to probe
these compounds in cells. Interestingly, distinct dark inclusions
were noted in the presence of compounds. These inclusions
appeared to resemble the size, number, and distribution to the
drug inclusions observed by transmission light microscopy.
■ CONCLUSIONS
This work begins the process of evaluating tools for detecting
large nano-entities. We found some strengths and weaknesses
of a set of techniques, which nonetheless together have allowed
us to reveal features of nano-entities from the atomic level to
the micrometer scale. It was noted that these large nano-
entities can adopt a variety of sizes and types that highly
depend on the solution conditions. It was also conﬁrmed that
compounds that form nano-entities can indeed enter cells, and
will certainly have properties (e.g., see ref 20).
However, it is still unclear where nano-entities can enter
cells as the monomer form versus aggregate form. Perhaps this
is cell and aggregate dependent. Others suggest that colloids do
not,15,16 whereas we observe compounds that have colloidal
forms and can enter cells. The exact mechanism of entry
remains unknown.
Another important point is whether the compounds exist in
cells as self-associated aggregates or subcellular localized with
organelles. Perhaps both occur. The self-association into
aggregates certainly helps to augment the observed ﬂuo-
rescence signal (see Figures 4 and S1−S5) as compared to a
ﬂuorescent compound Tartrazine that behave as lone-tumbling
molecules and have low signal-to-noise (Figure S7). Certainly,
colocalization also occurs. Figure S1 suggests that Lapatinib
can colocalize with lysosomes. To better address the question
of intracellular self-association, further studies are warranted
involving the lack and addition of tween. Unfortunately, the
toxicity of some compound studies here impeded such
experiments.
It is our assessment that the scientiﬁc community has only
begun to reveal this fascinating drug nano-world. First, a
platform of techniques needs to be established, which will
allow the scientiﬁc community to characterize nano-entities
then establish their correlation with salient properties. For
example, it has already been established that large-nano-entities
can be correlated with compounds high bioavailability,
promiscuity, false-positives in screens, and so forth. Perhaps
a better understanding of nano-entities can help minimize drug
side eﬀects, promote safer compounds to the clinic, or to serve
as drug delivery systems. For example, the corresponding
author has used the detection of aggregates to deprioritize
promiscuous drug candidates and promote selective com-
pounds for the clinic.12,22,23
■ EXPERIMENTAL SECTION
Compounds (Drugs and Dyes). Drugs and dyes used in
this study were obtained from commercial vendors. CAS
numbers are as following: Sorafenib (284461-73-0) from
Synchem, Inc.; Fulvestrant (129453-61-8) from Sigma;
Lapatinib (388082-78-8) from Larid Road; Clofazimine
(2030-63-9) from Sigma; Tartrazine (1934-21-0), and Light
green SF yellowish (5141-20-8) from Alfa Aesar. Alexa ﬂuor
WGA555 and Prolong Diamond Anti-fade with DAPI was
purchased from Thermo Fisher Scientiﬁc.
Transmission Electron Microscopy. Compounds were
diluted in 50 mM sodium phosphate pH 7.4 and in DMEM 5%
FBS. Next, 100 μL of the samples were transferred into a 240
μL Airfuge tube. A carbon-coated copper grid was inserted into
the bottom of the Airfuge tube with ﬁne tweezers and
centrifuged for 5 min at 20 psi. The carbon grid was gently
removed with tweezers and washed with distilled water, and
the carbon grid was negatively stained with 3% of
phosphotungstic acid (PTA-3). The grid was removed, blotted,
and dried with a bibulous paper, then examined by
transmission electron microscope (Hitachi H-7100). The
photographs were processed with the digital camera AMT
version 600.147.
Cell Culture. HeLa and Huh-7 cell lines were maintained in
DMEM supplemented with 5% of FBS albumin and in 1%
penicillin/streptomycin.
Confocal Laser Scanning Microscopy. CLSM was
employed to observe the self-aggregation of compounds within
the cells. HeLa and Huh-7 cells were grown on glass coverslips
in 24 well plates and cultured overnight in DMEM (5% FBS,
1% penicillin/streptomycin) at 37 °C in 5% CO2. Cell culture
media was removed and washed twice with PBS (50 mM
sodium phosphate, 100 mM sodium chloride). Compounds at
the given concentrations were added to the wells. After 1, 2, 4,
6, and 24 h of incubation, the cells were washed twice with 1×
PBS (50 mM sodium phosphate, 100 mM sodium chloride)
and treated with Alexa Fluor WGA555 for membrane staining.
The cells were then ﬁxed in 4% paraformaldehyde solution for
10 minutes and washed twice with PBS 1×. Further, the
coverslips were mounted on a prolong diamond antifade with
DAPI nucleus staining for Clofazimine and Light green SF
yellowish and DRAQ-5 for Lapatinib. The cells were imaged
by a Zeiss CLSM-780 confocal microscopy (ZEISS, Jena,
Germany) on an Olympus FV1000 at 60× magniﬁcation, using
the excitation and emission wavelengths for DAPI, excitation
was at 405 nm and emission at 460 nm; for Alexa Fluor
WGA555, excitation and emission were at 520 and 550 nm,
respectively. Compound excitation and emission information
are as follows: Clofazimine excitation (460−495 nm) and
emission (515−550 nm), Lapatinib excitation (405 nm) and
emission 460 nm), and Light green SF yellowish excitation
(405 nm) and emission (460 nm).
Cell Proliferation Assay and in Vitro Cytotoxicity
Study (MTT Assay). The cytotoxicity of the panel of
compounds and DMSO were evaluated in vitro using MTT
assays. HeLa and Huh-7 cells were plated in 96-well plates and
cultured overnight in DMEM 5% FBS, in the absence or
presence of compounds. After removing the culture medium,
various concentrations of the compounds added to the cells,
and incubated for 24 h. The medium in each well was then
aspirated and discarded. Next, 10 μL of 5 mg/mL MTT
solution 3-(4,5-dimethylthiazol-2,5-diphenyl tetrazolium bro-
mide), was added to each well and incubated for 2 to 4 h.
Following incubation, the medium was replaced with 150 μL
DMSO solution. After 15 min, the optical densities at 570 nm
were measured by spectrophotometer.
Dynamic Light Scattering. Compounds were measured
in DMEM 5% FBS or phosphate buﬀer, pH 7.4. Measurements
were performed by polystyrol/polystyrene 10 × 10 × 45 mm
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cuvettes, utilizing the Zetasizer Nano ZS (Malvern), version
1.7, with a 60 mW laser operating at 830 nm and a detector
angle of 158°. All samples were centrifuged before analysis
performed in triplicate at 25 °C and the data were acquired
using the Dynamics software. Compounds were at 50 μM.
Nuclear Magnetic Resonance. Compounds were pre-
pared from 20 mM DMSO stock solutions into buﬀer
consisting of 50 mM sodium phosphate pH 7.4 and 10%
D2O. DMSO samples were prepared by diluting the stock
samples. NMR data was acquired on a Bruker 600 MHz NMR
spectrometer equipped with a helium cryoprobe.10,12
Thin-Section Electron Microscopy. The cells were plated
at 1 × 105 cells/well and incubated in the presence of 50 μM of
all compounds for 24 h. The medium was then aspirated, and
the cells washed two times with 1× PBS. The cells were then
ﬁxed with glutaraldehyde (2.5% in 0.1 M cacodylate buﬀer or
phosphate-buﬀered saline, overnight) and again washed 2×
with PBS. Next, the cells were collected and centrifuged at
1000g for 10 min. The ﬁxed-cell pellets were resuspended in a
freshly prepared solution 1.3% (w/v) osmium tetroxide in a
colliding buﬀer for 1−2 h and then dehydrated by successive
washes with 25, 50, 75, and 95% solutions of acetone in water
(15−30 min each). This was followed by two changes of pure
acetone incubated for 30 min each. The cell pellets were then
resuspended in SPURR acetone (1:1) and incubated for 16−
18 h at room temperature. The cells were cut into small pieces
and placed in BEEM capsules to capacity. The capsules were
incubated at 600−650 °C for the polymerization reaction to
occur. The ﬁnal stage involved cutting the embedded cells into
ultrathin sections and placing the sections on a carbon-covered
copper 200-mesh grid. The grids were then stained with 50%
ethanol for 20−25 min. Examination of the sections was
performed using an electron microscope (Hitachi H-7100),
and the photographs were processed using the digital camera
AMT, version 600.147.
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